Finding Maximum Tolerated Dose in Phase I Oncology Clinical Trials with Bayesian Methods

被引：0
|
作者：
Sapi, Johanna [1 ,2 ]
机构：
[1] Obuda Univ, Biomat & Appl Artificial Intelligence Inst, John von Neumann Fac Informat, Becsi Ut 96-B, H-1034 Budapest, Hungary
[2] Obuda Univ, Univ Res & Innovat Ctr, Physiol Controls Res Ctr, Becsi Ut 96-B, H-1034 Budapest, Hungary
来源：
ACTA POLYTECHNICA HUNGARICA | 2024年 / 21卷 / 06期
关键词：
maximum tolerated dose (MTD); dose-limiting toxicity (DLT); Continual Reassessment Method (CRM); Time-To-Event Continual Reassessment Method (TITE- CRM); copula regression model; logistic regression model; delayed toxicities; late-onset toxicity model; CONTINUAL REASSESSMENT; DESIGN; TOXICITY; COMBINATIONS; AGENT;
D O I：
暂无
中图分类号：
T [工业技术];
学科分类号：
08 ;
摘要：
Maximum tolerated dose (MTD) is a maximal amount of drug or radiation resulting relatively acceptable dose-limiting toxicity (DLT). Accurate value of MTD should be found in Phase I trials in order to create the possibility to conduct successful Phase II (pilot efficacy and safety evaluation) and Phase III (comparative efficacy) trials. The aim of this paper is to review the difficulties of the dose-finding methods including multi-agent problems and late-onset toxicities, and to discuss Bayesian adaptive dose-finding methods which can handle these issues.
引用
收藏
页码：129 / 145
页数：17
相关论文
共 50 条
12345